Acetyl Hexapeptide-8

CosmeticCosmetic SNARE-targeting peptideExperimental

Also known as: Argireline, Acetyl Hexapeptide-3

Acetyl Hexapeptide-8 (also called Argireline or Acetyl Hexapeptide-3) is a cosmetic SNARE-targeting peptide. Acetyl hexapeptide-8, commonly sold as Argireline, mimics the N-terminal sequence of SNAP-25, one of the three SNARE proteins that assemble to fuse neurotransmitter vesicles with the presynaptic membrane.

Calculate Dose

For research use only.

Key Facts

CAS
616204-22-9
Molecular Weight (MW)
—
Half-life
Topical; systemic PK not established
FDA status
Not Approved
Evidence level
Limited Human Evidence
Human dose established
No
Administration Route
Not established in humans
Frequency
Not established in humans
Last updated
Nov 7, 2026
Reviewed
Nov 7, 2026
Targets
SNAP-25 / SNARE complex

Vendor price snapshot

None of these listings has a price per mg to compare. From public vendor listings; confirm the live price on the vendor site. Peptide Library does not sell peptides.

Vendors listing this peptide
3
Listed offers
3
Price per mg (peptide vials)
—

By form

Each form is priced on its own: a price per mg doesn't make a spray or a capsule equivalent to a vial.

Open calculator · Compare vendors

Research summary

Topical hexapeptide (Argireline) used in cosmetics as a SNAP-25 fragment analog. Marketed to soften expression lines; not an FDA-approved drug.

Research evidence

  • Regulatory review (FDA label)None in reviewed sources
  • Controlled human trials4 reviewed sources
  • Early or uncontrolled human studiesNone in reviewed sources
  • Lab & animal studies1 reviewed source
How it works

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

Peptide Library's Acetyl Hexapeptide-8 profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Acetyl Hexapeptide-8 dosage: no established human dose

Acetyl hexapeptide-8 (Argireline) has no established human dosage. It is a cosmetic ingredient applied to the skin, and its human studies test creams, gels and lotions at stated strengths (0.005% to 10%), not a dose. A randomised placebo-controlled study in 60 adults applied it to the skin around the eyes twice daily for 4 weeks. No study has injected it.

Limited Human Evidence

No established human dosage.

Human clinical evidence: None identified.

Preclinical research: Acetyl hexapeptide-8 is a six-amino-acid peptide modelled on part of the SNAP-25 protein and used in anti-wrinkle cosmetics. Its human evidence is small studies of topical products, mostly over weeks to a few months, and two small blepharospasm trials, one of them terminated. In a laboratory test on human skin, almost none of a 10% cream passed the outer skin layer. There is no human study of injected acetyl hexapeptide-8, so no injectable amount, route or interval is established.

Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.

Dosage evidence summary for Acetyl Hexapeptide-8
Human dosing establishedNo
RouteTopical (in all human studies)
FrequencyTwice daily in the published topical studies
Duration studied4 weeks to 3 months in the published topical studies
Evidence levelLimited Human Evidence
Last reviewed2026-11-07

Human research reported

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Acetyl Hexapeptide-8, one row per studied regimen
Study / contextPopulationDoseRouteFrequencyDurationOutcome studiedSource
Randomised placebo-controlled study — periorbital wrinkles (Wang et al., 2013)Clinical trial · Randomised placebo-controlled trial of a topical product60 Chinese adults with periorbital wrinkles, randomised 3:1 to argireline or placeboConcentration not stated in the indexed abstractTopical (periorbital wrinkles)Twice daily4 weeksSubjective anti-wrinkle efficacy 48.9% with argireline vs 0% with placebo; skin-replica roughness parameters fell with argireline (p < 0.01) but not with placeboWang Y et al. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013.
NCT00942851 — randomised, triple-blind, phase 1/2, completed, results postedClinical trial · Registered randomised trial with posted results24 people with blepharospasm (focal dystonia); the registry describes benefit as added to botulinum toxin injectionTopical cream containing 0.005% AH-8 vs identical cream without itTopical——Posted mean time until the Jankovic Blepharospasm Rating Scale returned to baseline: 3.71 months with AH-8 vs 3.03 months with placeboNCT00942851 — A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm
NCT01750346 — randomised, double-blind, phase 2, terminated, results postedClinical trial · Registered randomised trial, terminated, with posted results8 people with blepharospasm (focal dystonia) in three arms0.05% or 0.025% AH-8 vs placeboTopical—2 months (primary time point)Posted Jankovic Blepharospasm Rating Scale at 2 months: 6 (0.05%), 7 (0.025%) and 4.33 (placebo)NCT01750346 — Acetyl Hexapeptide-8 for Blepharospasm
NCT01381484 — randomised, triple-blind, phase 3, completed, no results postedClinical trial · Registered randomised trial, no results posted70 adults with periorbital wrinkles (actual enrolment)Gel containing 10% Argireline vs placebo gelTopical (face and periorbital area)Twice daily3 monthsNo results posted on the registryNCT01381484 — Argireline in Treatment of Periorbital Wrinkles
Randomised double-blind trial — crow's feet (Aruan et al., 2023)Clinical trial · Small randomised controlled trial of topical creams21 Indonesian women aged 26–55 with crow's feet, split into three groups: acetylhexapeptide-3 cream, palmitoyl pentapeptide-4 cream and placeboCream concentration not stated in the indexed abstractTopical (periorbital area)Twice daily8 weeksImprovements in several subjects with both creams; the authors reported better results with palmitoyl pentapeptide-4 than with acetylhexapeptide-3 (another INCI name for this peptide) and called it an initial study needing more subjectsAruan RR et al. Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet. J Clin Aesthet Dermatol. 2023.

Preclinical and analog research

Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.

Research-reported dosing for Acetyl Hexapeptide-8, one row per studied regimen
Study / contextPopulationDoseRouteFrequencyDurationOutcome studiedSource
Laboratory study — skin penetration from a cream (Kraeling et al., 2015)Preclinical · In vitro skin penetration studyHuman cadaver skin and hairless guinea pig skin in diffusion cellsOil-in-water emulsion with 10% peptide applied at 2 mg/cm² for 24 hours (not a human dose)Applied to excised skin——Most peptide washed off the surface; 0.22% of the applied amount stayed in human stratum corneum and 0.01% reached the epidermis; none was detected in the dermis or the fluid below the skinKraeling ME et al. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. 2015.

Where sources disagree

  • A percentage or ppm in a cream is a formulation strength, not a dose, and cannot be converted into an amount for injection.
  • A powder listed as a vial is also sold. No human study has injected acetyl hexapeptide-8 at any amount, so protocols for injection have no primary source.
  • Acetyl hexapeptide-3 is another name for the same peptide. Combination products that also contain other actives are not evidence for this peptide alone.

Reconstitution

These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.

Calculate reconstitution & dose →

Handling & administration

Concentration Example
Typical 0.005–0.01% (brand literature)

Sequence & molecular data

Sequence and molecular data for Acetyl Hexapeptide-8
Amino acid sequenceGlu-Glu-Met-Gln-Arg-Arg
Molecular formulaVaries by salt/hydration (see PubChem/INCI)
Molecular weight—
CAS number616204-22-9
Half-lifeTopical; systemic PK not established
AppearanceWhite powder
FormulationTopical Cream
PubChem CID71587772
FDA UNIIL4EL31FWIL
DrugBankDB11709

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

Acetyl hexapeptide-8, commonly sold as Argireline, mimics the N-terminal sequence of SNAP-25, one of the three SNARE proteins that assemble to fuse neurotransmitter vesicles with the presynaptic membrane. By competing for a position in the SNARE complex it is reported to destabilise assembly, reducing calcium-dependent catecholamine and acetylcholine release in model systems. The intended cosmetic consequence is reduced contraction of facial expression muscles and therefore softened dynamic lines — a mechanism conceptually parallel to botulinum toxin, which cleaves SNAP-25 enzymatically, but far weaker and non-enzymatic. The central open question is topical delivery: a hydrophilic hexapeptide penetrates intact stratum corneum poorly, and most supporting data comes from small formulation studies.

Origin

Synthetic acetylated hexapeptide used as a cosmetic active.

Targets

SNAP-25 / SNARE complex

Research statistics

37 PubMed publications · 35.1% human clinical research · 3 registered trials

Counts of published research through 2026-11-15, not evidence that it works. Publications by year, study types and trials · How publications are counted

Regulatory & research status

Acetyl Hexapeptide-8 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

Regulatory and research status for Acetyl Hexapeptide-8
FDA statusNot Approved
AvailabilityOTC / Supplement
WADA (sport)Permitted
Library classificationResearch-Only

How FDA approval, compounding and research-only status differ

Benefits

Topical expression-line researchCosmetic skin-smoothing claimsNon-injectable cosmetic use

Acetyl Hexapeptide-8 side effects

Acetyl Hexapeptide-8 has only limited human data, so the list below is incomplete and its side-effect profile is not well established.

Side Effects

  • Mild irritation
  • Redness
  • Contact dermatitis (uncommon)

Stacking

Common stacking partners

acetyl-octapeptide-3

Combinations that include Acetyl Hexapeptide-8, with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.

Storage & stability

Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.

Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.

Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.

Cosmetic peptides in this library are formulated into topical products; follow the product label rather than the reconstitution guidance above.

Read the full guide: how to store peptides before and after reconstitution →

Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.

Acetyl Hexapeptide-8: frequently asked questions

What is Acetyl Hexapeptide-8?

Topical hexapeptide (Argireline) used in cosmetics as a SNAP-25 fragment analog. Marketed to soften expression lines; not an FDA-approved drug.

How does Acetyl Hexapeptide-8 work?

Acetyl hexapeptide-8, commonly sold as Argireline, mimics the N-terminal sequence of SNAP-25, one of the three SNARE proteins that assemble to fuse neurotransmitter vesicles with the presynaptic membrane. By competing for a position in the SNARE complex it is reported to destabilise assembly, reducing calcium-dependent catecholamine and acetylcholine release in model systems.

Is Acetyl Hexapeptide-8 FDA approved?

No. Acetyl Hexapeptide-8 is not approved by the FDA for any indication and is categorised as otc / supplement. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

What is the half-life of Acetyl Hexapeptide-8?

Reported half-life for Acetyl Hexapeptide-8 is Topical; systemic PK not established. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

What is the amino acid sequence of Acetyl Hexapeptide-8?

Acetyl Hexapeptide-8 has the sequence Glu-Glu-Met-Gln-Arg-Arg, giving a chain of 6 amino acids. Its molecular formula is Varies by salt/hydration (see PubChem/INCI).

Is Acetyl Hexapeptide-8 banned in sport?

Acetyl Hexapeptide-8 is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2

This Acetyl Hexapeptide-8 profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track Acetyl Hexapeptide-8 research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →